Anatumomab mafenatox
Anatumomab mafenatox is a mouse monoclonal antibody studied for the treatment non-small cell lung cancer,[1] which acts as a tumor-targeted superantigen.[2]
Monoclonal antibody | |
---|---|
Type | Fab fragment |
Source | Mouse |
Target | TAG-72 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
(verify) |
It is a fusion protein of a human tumor-associated 5T4 antigen monoclonal IgG1 Fab fragment with an enterotoxin ('mafenatox') of Staphylococcus aureus.[3]
Development was abandoned in 2005.[4]
References
- "Active Biotech". activebiotech.com. Retrieved 25 May 2016.
- Hedlund, Gunnar; Forsberg, Göran; Nederman, Thore; Sundstedt, Anette; Dahlberg, Leif; Tiensuu, Mikael; Nilsson, Mats (2013). "Tumor-Targeted Superantigens": 365–381. doi:10.1002/9781118354599.ch24. Cite journal requires
|journal=
(help) - "Drug info" (PDF). World Health Organisation. Retrieved 25 May 2016.
- http://adisinsight.springer.com/drugs/800013422
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.